Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK)
of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with
CML chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph+ ALL, who have
experienced resistance or intolerance to at least three tyrosine kinase inhibitors (TKIs).